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Abstract. To elucidate the mechanism of action of prostaglandin I2 (PGI2) 
and carbaprostacyclin we studied their effect on DNA synthesis and 
proliferation in primary cultures of adult rat hepatocytes. Hepatocyte 
parenchymal cells, maintained in a serum-free, defined medium, 
synthesized DNA and proliferated in the presence of PGI2 (10-8 M) or 
carbaprostacyclin (10-9 M) in a time- and dose-dependent manner. PGI2 was 
less potent than carbaprostacyclin in stimulating hepatocyte mitogenesis. 
These effects of PGI2 and carbaprostacyclin were abolished by treatment 
with a specific IP receptor antagonist, CAY10441 (10-9 ~10-7 M), and by the 
thromboxane A2 receptor agonist, U46619 (10-7 M). Hepatocyte mitogenesis 
induced by the IP receptor agonists was almost completely blocked by 
specific inhibitors of growth-related signal transducers such as AG1478 (5 × 
10-7 M), LY294002 (10-7 M), PD98059 (10-6 M), and rapamycin (10 ng/ml). 
In addition, PGI2 or carbaprostacyclin significantly increased the kinase 
activity of a (p175 kDa) receptor tyrosine kinase and the phosphorylation of 
p42 kDa mitogen-activated protein (MAP) kinase. Addition of a monoclonal 
antibody against transforming growth factor (TGF)-α, but not insulin-like 
growth factor-I, to the culture dose-dependently inhibited the PGI2- or 
carbaprostacyclin-induced hepatocyte mitogenesis. These results suggest 
that the IP receptor agonist-induced hepatocyte mitogenesis is mediated by 
autocrine secretion of TGF-α followed by activation of a receptor tyrosine 
kinase/MAP kinase pathway. 
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Introduction 
 
Prostaglandins (PGs) have diverse biological functions as chemical 
mediators for the maintenance of local homeostasis in nearly all 
mammalian tissues, including regulatory functions linked to inflammation, 
platelet aggregation, and contraction of smooth muscles (1). In addition, 
prostaglandins are also reported to be involved in liver regeneration. Thus 
prostaglandin E2 (PGE2) increases in rat liver after partial hepatectomy. 
Furthermore, indomethacin both inhibits DNA synthesis in regenerating 
liver and prevents increases in PGE2 (2-6). 
We have previously shown that each prostaglandin from a different series 
can stimulate DNA synthesis and proliferation in serum-free primary 
cultures of adult rat hepatocytes (7). These findings were unexpected since 
prostaglandins are regarded as co-mitogenic growth factors that enhance 
the effects of primary mitogens such as insulin and EGF (8, 9). Among 
these prostaglandins tested the PGI2 receptor (IP receptor) agonist was of 
particular interest, as, to date there has been almost no report of its 
involvement in the stimulation of DNA synthesis and proliferation of 
primary cultures of adult rat hepatocytes. 
PGI2 (prostacyclin) was isolated from eluates of the stomach fundus and 
the vascular endothelium, along with prostaglandin endoperoxides. It is 
well known that PGI2 is synthesized mainly by the vascular endothelium 
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and that it is a powerful vascular vasodilator and inhibitor of platelet 
aggregation (10). In contrast, thromboxane A2 has antagonistic properties 
(vasoconstriction, aggregation of platelets) and opposes the actions of PGI2 
on platelets (11). However, relatively little is known about IP receptor 
effector mechanisms during liver regeneration, although binding sites have 
been described for PGI2 (12). 
Recently, various types of receptors for PGE2, PGF2α, PGI2, PGD2, and 
thromboxane A2 (i.e., EP, FP, IP, DP, and TP receptors, respectively) have 
been characterized using pharmacological and biochemical approaches (1, 
13-15). Prostaglandin receptors are members of the superfamily of G 
protein-coupled receptors that appear to have a single subunit structure 
containing seven membrane-spanning regions. 
The main purpose of the present study was to investigate the 
growth-promoting effects of IP receptor agonists, including the 
naturally-occurring PGI2 agonist and the more stable analog, 
carbaprostacyclin, on DNA synthesis and proliferation in primary cultures 
of adult rat hepatocytes. In addition, we investigated the role of the IP 
receptor in mediating the effect of these prostanoids on intracellular signal 
transduction, as well as possible physiological antagonism by TP receptor 
agonists. Our results suggest that the IP receptor mediates the 
proliferative actions of the prostanoids on primary cultured hepatocytes via 
induction of autocrine secretion of transforming growth factor (TGF)-α, and 
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subsequent activation of a tyrosine kinase/MAP kinase pathway. 
 
 
Materials and Methods 
 
Animals 
Male Wistar rats weighing 200 - 220 g were obtained from Saitama 
Experimental Animal Co. (Tokyo, Japan). Adaptation to a light-, humidity- 
and temperature-controlled room occurred over a minimum 3-day period 
prior to the start of the experiments. Rats were fed a standard diet and 
given tap water ad libitum. The animals used in this study were handled in 
accordance with the “Guiding Principle for the Care and Use of Laboratory 
Animals” approved by the Japanese Pharmacological Society. 
 
Hepatocyte isolation and culture 
Rats were anesthetized by intraperitoneal injection of sodium 
pentobarbital (45 mg/kg). Hepatocytes were isolated from normal livers by 
a two-step in situ collagenase perfusion technique to facilitate 
disaggregation of the adult rat liver (16, 17). In brief, dispersed hepatocytes 
were washed three times by slow centrifugation (50 × g, 1 min) of the cell 
suspension to remove cell debris, damaged cells and non-parenchymal cells. 
Viability was more than 97% as tested by Trypan blue exclusion. Unless 
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otherwise indicated, freshly isolated hepatocytes were plated onto 
collagen-coated plastic culture dishes (Sumitomo Bakelite Co., Tokyo, 
Japan) at a density of 3.3 × 104 cells/cm2 (3.0 × 105 cells/35-mm dish), and 
allowed to attach for 3 h in Williams’ medium E containing 5% newborn 
calf serum, 0.1 nM dexamethasone, 100 U/ml penicillin, 100 μg/ml 
streptomycin and 0.10 μg/ml aprotinin in 5% CO2 in air at 37ºC. The 
medium was then replaced by aspiration, and the cells were further 
cultured in serum- and dexamethasone-free Williams’ medium E 
supplemented with prostaglandins such as PGI2 and carbaprostacyclin. 
When appropriate, IP receptor agonists with or without CAY10441, 
SC-51322, U-73122, U-73343, sphingosine, H-89, 2,4-dideoxyadenosine, 
ionomycin, verapamil, somatostatin or the growth-related signal 
transduction inhibitors AG1478, LY294002, PD980059, or rapamycin were 
added at the concentrations indicated in the text. 
 
Measurement of DNA synthesis 
Hepatocyte DNA synthesis was assessed by measuring the incorporation 
of [3H]thymidine into acid-precipitable materials. Briefly, after an initial 
attachment period of 3 h, the hepatocytes were washed twice with 
serum-free Williams’ medium E and cultured in a medium containing IP 
receptor agonists with or without agents to be tested for an additional 4 or 
21 h. The cells were pulsed with [3H]thymidine (1.0 μCi/well) at 1, 2, 3 or 19 
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h after a 2-h prostaglandin stimulation followed by 10% trichloroacetic acid 
precipitation, as described previously (18). [3H]Thymidine incorporation 
into DNA was counted as counts per min using a scintillation counter and 
was normalized for cellular protein. Aphidicolin (10 μg/ml) was added to 
some wells to establish the level of non-replicative DNA synthesis. 
Hepatocyte protein content was measured by a modified Lowry procedure 
using bovine serum albumin as the standard (19). Data are expressed as 
dpm/h/mg cellular protein. 
 
Nuclei counting 
The number of nuclei, rather than the number of cells, was counted using 
a modified version of a previously described procedure (20, 21). Briefly, 
primary cultured hepatocytes were washed twice with 2 ml of Dulbecco’s 
phosphate-buffered saline (PBS, pH 7.4). Isolated liver cell nuclei were 
then prepared for quantification by exposure of the cultured hepatocytes to 
0.25 ml of citric acid (0.1 M) containing Triton X-100 (0.1%) for 30 min at 
37ºC. An equal volume of the nuclear suspension was mixed with Trypan 
blue (0.3%) in PBS (pH 7.4) and the number of nuclei was counted in a 
hemocytometer. 
 
Determination of receptor tyrosine kinase activity 
A 175-kDa protein was identified as the EGF/TGF-α receptor by 
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immunoblotting with a specific anti-phospho-receptor tyrosine kinase 
antibody according to the manufacturer’s instructions. In brief, hepatocytes 
were freshly isolated and seeded at a density of 3.3 × 104 cells/cm2 and 
cultured in Williams’ medium E containing 5% newborn bovine serum. The 
medium was then replaced by aspiration and the cells were further 
cultured in serum- and dexamethasone-free Williams’ medium E. Cultured 
hepatocytes were washed once with ice-cold phosphate-buffered saline (pH 
7.4) and then 0.2 ml lysis buffer [20 mM Tris buffer, pH 7.5, 1% Triton 
X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 1 mM β-glycerophosphate, 1 
mM phenylmethylsulfonyl fluoride] was added. Cell lysates were obtained 
by scraping the cells in lysis buffer followed by sonication for 3 min. Cell 
lysates were spun down (3000 × g for 3 min at 4°C), and then denatured in 
boiling water for 5 min. For immunoblotting analysis, samples of the 
supernatant (30 μg/lane) were resolved by SDS-polyacrylamide gel 
electrophoresis, using a 7.5% polyacrylamide resolving gel (22), transferred 
to PVDF membrane and immunoblotted with the anti-phosphotyrosine 
antibody PY 20 (23). Blots were developed by enhanced chemiluminescence 
following incubation with HRP-conjugated secondary antibodies (24). 
Proteins were quantified by densitometry after the membrane was 
developed with enhanced chemiluminescence reagent and exposure to 
Hyperfilm (Kodak). Densitometric analysis was performed using the NIH 
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image program (ver. 1.6 for Macintosh). The tyrosine kinase activity 
(autophosphorylation) of the phosphorylated p175 kDa protein (P-p175 
kDa) was normalized to that of the total p175 kDa protein. The 
supernatant protein concentration was determined using the Bio-Rad DC 
protein assay. 
 
Determination of MAP kinase activity 
Phosphorylated (activated) MAP kinase isoforms (p42 and p45) were 
identified by western blot analysis of cell lysates using a 1:1000 dilution of 
rabbit polyclonal dual phospho-specific antibodies (1 mg/ml) with 
HRP-conjugated goat anti-rabbit IgG as a secondary antibody, as 
previously described (23). Cell lysis and western blotting procedures were 
carried out as described in the previous section except that 20 μg of the 
supernatant was applied/lane of a 10% polyacrylamide resolving gel. 
Phosphorylated MAP kinase (P-42 MAP kinase) activity was normalized to 
the total MAP kinase activity. The data were calculated in arbitrary units 
and are expressed as means ± S.E.M. (*P < 0.05 when compared to the 
medium alone). The autodiagram is a representation of three experiments 
using different cell preparations. 
 
Neutralization of endogenous growth factors 
In experiments employing neutralizing antibodies, serum-free primary 
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cultured hepatocytes were treated with varying concentrations of IP 
receptor agonists in the presence or absence of monoclonal antibodies 
against IGF-I or TGF-α (12.5, 25, 50, 75 or 100 ng/ml). 
 
Materials 
The following reagents were obtained from Sigma Chemical Co. (St. Louis, 
MO, USA): aphidicolin, ionomycin, dexamethasone, somatostatin, 
verapamil hydrochloride, and aprotinin. Monoclonal antibodies against 
IGF-I and TGF-α, as well as SC-51322 
(2-[3-[(2-furanylmethyl)-thiol]-1-oxopropyl]hydrazide), U-73122 
(1-[6-[17β-3-methoxyestra-1,3,5(10)-trien-17-yl]-amino] hexyl]-1H-pyrrol-2, 
5-dione), U-73343 (1-[6-[17β-3-methoxyestra-1,3,5(10)-trien-17-yl]-amino] 
hexyl]-2, 5-pyrrolidine-dione), sphingosine, 2,4-dideoxyadenosine, H-89 
(N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide 
dihydrochloride), AG1478 
(2-[4-morpholinyl]-8-phenyl-1(4H)-benzopyran-4-one), LY294002 
(N-[3-chlorophenyl]-6,7-dimethoxy-4-quinazolinamine), and rapamycin, 
were obtained from Biomol Research Laboratories, Inc. (Plymouth Meeting, 
PA, USA). CAY 10441 (4,5-dihydro-N-[4-[[4-(1-methylethxy)phenyl] 
methyl]-1H-imidazol-2-amine) was obtained from Cayman Chemical Co. 
(Ann Arbor, MI, USA). PD98059 (2’-amino-3’-methoxyflavone) was obtained 
from Calbiochem-Behring (La Jolla, CA, USA). Williams’ medium E and 
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newborn calf serum were purchased from Flow Laboratories (Irvine, 
Scotland). Collagenase (type II) was obtained from Worthington 
Biochemical Co. (Freehold, NJ, USA). [Methyl-3H] thymidine (20 Ci/mmol) 
was purchased from DuPont-New England Nuclear (Boston, MA, USA). All 
other reagents were of analytical grade. 
 
Statistical analysis 
Data are expressed as means ± S.E.M. Group comparisons were made by 
analysis of variance (ANOVA) for unpaired data followed by post hoc 
analysis using Dunnett’s multiple comparison test. Differences of P < 0.05 
were considered to be statistically significant. 
 
 
 
Results 
 
Time course of induced stimulation of hepatocyte DNA synthesis and 
proliferation by IP receptor agonists 
We first examined the effects of IP receptor agonists on DNA synthesis 
and proliferation in primary cultures of adult rat hepatocytes in the 
absence of exogenously added peptide growth factors. When maintained for 
a short time in culture medium containing PGI2 (10-8 M) or 
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carbaprostacyclin (10-9 M) the hepatic parenchymal cells underwent 
time-dependent DNA synthesis and proliferation (i.e., an increase in the 
number of nuclei). The onset of DNA synthesis was first observed about 2.5 
h after the addition of PGI2 or carbaprostacyclin (Fig. 1A), while mitotic 
activity of the hepatocytes was first observed at about 3.0 h and peaked at 
4.0 h (Fig. 1B). Maximal stimulation of hepatocyte DNA synthesis and 
proliferation by PGI2 and carbaprostacyclin was approximately 6.0-fold and 
1.3-fold, respectively. 
 
Dose-response effects of IP receptor agonists on hepatocyte DNA synthesis 
and proliferation 
We next examined the dose-response relationship between the IP receptor 
agonists and DNA synthesis and proliferation in primary cultures of adult 
rat hepatocytes. PGI2-induced DNA synthesis was dose-dependent and 
reached a plateau at 10-8 M, with a half-maximal effective concentration 
(ED50) value of 1.0 × 10-9 M (Fig. 2A). Carbaprostacyclin-induced DNA 
synthesis was also dose-dependent and reached a plateau at 3 × 10-9 M, 
with an ED50 value of 1.8 × 10-10 M (Fig. 2A). Despite the fact that 
carbaprostacyclin was about one order of magnitude more potent than PGI2 
in stimulating hepatocyte DNA synthesis, the maximal response induced 
by carbaprostacyclin and PGI2 was almost the same. The proliferative 
effect (i.e., increase in the number of nuclei) of these IP receptor agonists 
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on cultured hepatocytes were very similar to their effects on DNA synthesis 
(Fig. 2B). In contrast the effect of U46619, a TP receptor agonist, on DNA 
synthesis and proliferation in cultured hepatocytes was negligible being in 
the concentration range of 10-12 to 10-7 M (Figs. 2A and 2B). 
 
Effects of specific IP receptor antagonists, EP receptor antagonists, and TP 
receptor agonists, on hepatocyte DNA synthesis and proliferation induced by 
IP receptor agonists 
To confirm that IP receptor agonist cellular effects were mediated by 
IP-receptors we investigated the effect of an IP receptor antagonist 
(CAY10441), EP1 receptor antagonist (SC-51322), or U46619 on IP receptor 
agonist-induced-hepatocyte DNA synthesis and proliferation after 4 h of 
culture. The DNA synthesis and proliferative effects of PGI2 (10-8 M) and 
carbaprostacyclin (10-9 M) on primary cultured hepatocytes were inhibited 
by CAY10441 (10-9 to 10-7 M) in a dose-dependent manner (Figs. 3A and 
3B). The effects of the IP receptor agonists on hepatocyte DNA synthesis 
and proliferation were not inhibited by SC-51322 (10-10 to 10-7 M). Although 
addition of U46619 (10-7 M) alone did not affect hepatocyte DNA synthesis 
or proliferation (Figs. 2A and 2B) U46619 did inhibit IP receptor 
agonist-induced hepatocyte DNA synthesis and proliferation in a 
dose-dependent manner (Figs. 3A and 3B). 
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Effects of inhibitors or stimulators of signal-transducers, including 
adenylate cyclase/protein kinase A and the phospholipase C/Ca2+/protein 
kinase C pathway, on IP receptor agonist-induced hepatocyte DNA synthesis 
and proliferation 
We pharmacologically investigated the intracellular signal transduction 
events associated with IP receptor agonist treatment of primary cultured 
hepatocytes to determine how IP receptor agonists induce hepatocyte DNA 
synthesis and proliferation. To clarify whether IP receptor agonists 
stimulate hepatocyte DNA synthesis and proliferation via an adenylate 
cyclase/protein kinase A pathway, we investigated whether a direct 
inhibitor of adenylate cyclase, 2,4-dideoxyadenosine, or an inhibitor of 
protein kinase A, H-89, had inhibitory effects on hepatocyte mitogenesis 
induced by PGI2 (10-8 M) or carbaprostacyclin (10-9 M). Neither 
2,4-dideoxyadenosine (10-6 M) nor H-89 (10-7 M) affected IP receptor 
agonist-induced hepatocyte DNA synthesis or proliferation (Figs. 4A and 
4B), suggesting that adenylate cyclase and protein kinase A may not 
contribute to hepatocyte mitogenesis induced by these IP receptor agonists. 
Moreover, 2,4-dideoxyadenosine (10-6 M) and H-89 (10-7 M), when 
administered alone, did not significantly influence hepatocyte DNA 
synthesis or proliferation over 4 h of culture (data not shown). 
To characterize a possible involvement of the phospholipase C (PLC)/Ca2+ 
/protein kinase C pathway in IP-receptor-mediated stimulation of 
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hepatocyte DNA synthesis and proliferation induced by PGI2 or 
carbaprostacyclin, we investigated the effect of the specific PLC inhibitor, 
U-73122, and a protein kinase C inhibitor, sphingosine, on these responses. 
Addition of U-73122 (10-6 M) markedly attenuated PGI2-(10-8 M) and 
carbaprostacyclin- (10-9 M) stimulation of hepatocyte DNA synthesis and 
proliferation over 4 h of culture (Figs. 4A and 4B). Neither U-73343 (10-6 
M), a close structural analog of U-73122 with no inhibitory action on PLC, 
nor sphingosine (10-6 M), significantly affected PGI2 or 
carbaprostacyclin-induced hepatocyte DNA synthesis or proliferation over 4 
h of culture., The inhibitors alone did not produce any significant effects on 
hepatocyte DNA synthesis or proliferation (data not shown) over the 4-h 
incubation period. 
To determine the possible involvement of Ca2+ mobilization in PGI2- or 
carbaprostacyclin-induced hepatocyte DNA synthesis and proliferation, the 
cells were similarly treated with ionomycin, a Ca2+ ionophore, for 4 h. 
Significant potentiation of both PGI2- and carbaprostacyclin-induced 
hepatocyte DNA synthesis and proliferation was observed following 
ionomycin (10-7 M)treatment. These findings suggest that 
PLC-independent agents, that elevate intracellular Ca2+ levels, enhance 
PGI2 or carbaprostacyclin-induced hepatocyte mitogenesis. Conversely, the 
ability of PGI2 and carbaprostacyclin to stimulate hepatocyte DNA 
synthesis and proliferation was almost completely inhibited by Ca2+ 
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channel blockers such as verapamil (10-6 M). In addition, somatostatin (10-7 
M), which inhibits the release of certain gastrointestinal and pancreatic 
hormones (presumably by affecting decreases in cytosolic Ca2+), strongly 
inhibited hepatocyte DNA synthesis and proliferation induced by these IP 
receptor agonists. However, these inhibitors and stimulators by themselves 
did not influence hepatocyte DNA synthesis or proliferation over 4 h of 
culture (data not shown). 
 
Effects of specific inhibitors of growth-related signal-transducers on 
hepatocyte DNA synthesis and proliferation induced by PGI2 or 
carbaprostacyclin 
We next investigated whether the mitogenic responses of primary 
cultured hepatocytes to the IP receptor agonists were mediated by signal 
transducers such as receptor tyrosine kinases, phosphatidylinositol 
3-kinase, mitogen-activated protein (MAP) kinase kinase or ribosomal 
protein S6 kinase (p70 S6K), by using the corresponding specific inhibitors 
of these signal transducers: AG1478, LY294002, PD98059, and rapamycin, 
respectively. As shown in Figs. 5A and 5B, hepatocyte DNA synthesis and 
proliferation induced by PGI2 (10-8 M) or carbaprostacyclin (10-9 M) were 
almost completely inhibited by AG1478 (5 × 10-7 M), LY294002 (10-7 M), 
PD98059 (10-6 M) or rapamycin (10 ng/ml). The inhibitors by themselves 
did not affect hepatocyte DNA synthesis or proliferation over 4 h of culture. 
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Effect of specific inhibitors of growth-related signal transducers on receptor 
tyrosine kinase and MAP kinase activity induced by PGI2 or 
carbaprostacyclin 
To obtain further support for receptor tyrosine kinase/ MAP kinase 
mediation of the IP receptor agonist action, we examined the effects of 
specific inhibitors of growth-related signal transducers  on receptor 
tyrosine kinase and MAP kinase activities induced by IP receptor agonists. 
Figure 6A shows that PGI2 (10-8 M) or carbaprostacyclin (10-9 M) caused an 
increase in the tyrosine phosphorylation of a 175 kDa protein that peaked, 
20 min after addition, at about 3.0-fold (compared with control). When 
PGI2 or carbaprostacyclin were added in combination with AG1478 (5 × 10-7 
M), AG1478 completely abolished the IP receptor agonist-induced increase 
in receptor tyrosine kinase activity. In contrast, receptor tyrosine kinase 
activation induced by IP receptor agonists was not abolished by LY294002 
(10-7 M), PD98059 (10-6 M) or rapamycin (10 ng/ml) treatment. In addition 
the TP receptor agonist U46619 (10-7 M) abolished IP receptor 
agonist-induced receptor tyrosine kinase activation. 
PGI2 (10-8 M) and carbaprostacyclin (10-9 M) caused an increase in the 
phosphorylation of p42 MAP kinase, but not p44 MAP kinase, peaking at 
about 3.0-fold (compared with control) 20 min after addition (Fig. 6B). 
When the agonists were added in combination PD98059 (10-6 M), PD98059 
completely abolished the IP receptor agonist-induced increase in p42 MAP 
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kinase. Moreover, p42 MAP kinase activation induced by IP receptor 
agonists was abolished by AG1478 (5 × 10-7 M) or LY294002 (10-7 M), but 
not by rapamycin (10 ng/ml) treatment. In addition, U46619 abolished IP 
receptor agonist-induced p42 MAP kinase activation. 
 
Effects of monoclonal antibodies against TGF-α or IGF-I  on hepatocyte 
DNA synthesis and proliferation induced by PGI2 or carbaprostacyclin 
 The data in Figs. 4 - 6 show that IP receptor agonist-induced hepatocyte 
DNA synthesis and proliferation are mediated through both the IP 
receptor/(Gq)/PLC/Ca2+ pathway and a receptor tyrosine kinase/MAP 
kinase cascade. However, how these pathways interact with each other 
remains to be elucidated. Since prostaglandins mainly act as co-mitogens 
rather than as mitogens both in vivo and in vitro, we hypothesized that 
hepatocyte mitogenesis mediated by the IP receptor agonists might be due 
to selective induction of secretion of primary mitogens in an autocrine 
manner. Potential primary mitogenic candidates are TGF-α and IGF-I 
since hepatocytes express mRNA for TGF-α and IGF-I, and can synthesize 
and store these primary growth factors (9). 
To examine the possibility that TGF-α or IGF-I mediate IP 
agonist-induced hepatocyte DNA synthesis and proliferation in primary 
cultures, we examined the effect of addition of neutralizing monoclonal 
antibodies against TGF-α and IGF-I on these processes. Figure 7 shows 
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that addition of a neutralizing monoclonal antibody against TGF-α 
dose-dependently inhibited the growth-promoting effect of PGI2 (10-8 M) 
and carbaprostacyclin (10-9 M) on hepatocyte DNA synthesis and 
proliferation. The IC50 values for these effects on synthesis and 
proliferation after 4 h of culture were 25 and 35 ng/ml, respectively. In 
contrast, the DNA synthesis and proliferative effects of IP receptor agonists 
were not significantly affected by treatment of hepatocytes with various 
concentrations of a monoclonal antibody against IGF-I (12.5 - 100 ng/ml). 
These monoclonal antibodies by themselves did not significantly influence 
hepatocyte DNA synthesis and proliferation over 4 h of culture (data not 
shown). The results indicate that abrogation of the effects of PGI2 (10-8 M) 
and carbaprostacyclin (10-9 M) was specific for the antibody against TGF-α. 
 
 
Discussion 
 
 We have demonstrated that PGI2 and a stable analog of PGI2, 
carbaprostacyclin, significantly induce DNA synthesis and proliferation in 
primary cultures of adult rat hepatocytes in the absence of exogenously 
added primary growth factors (shown in Figs. 1 and 2). The 
growth-promoting effects of IP receptor agonists are almost completely 
inhibited by the IP receptor antagonist, CAY 10441. In contrast, the EP1 
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receptor subtype-specific antagonist SC-51322 (25) did not affect IP 
receptor agonist-induced hepatocyte DNA synthesis or proliferation (Fig. 3), 
confirming that the IP receptor agonists apparently act as complete 
mitogens via the IP receptor in primary cultures of adult rat hepatocytes. 
However, postreceptor mechanisms responsible for the proliferative action 
of the IP receptor agonists, as well as intracellular signal transduction 
mechanisms, remain to be clarified. Interestingly, it was found that the 
combination of IP receptor agonists and a TP receptor agonist U46619 
showed antagonistic effects on hepatocyte mitogenesis induced by IP 
receptor agonists. 
 It has been reported that signal transduction mechanisms that may serve 
as mediators for prostanoid receptors include 1) stimulation of adenylate 
cyclase via the Gs protein, 2) inhibition of adenylate cyclase via the Gi 
protein, 3) stimulation of phosphatidylinositol-phospholipase C (PLC) via 
Gq and, possibly, 4) elevation of intracellular Ca2+ through an 
phosphatidylinositol-dependent process (1). Although cAMP generation is 
generally regarded as the sole signal transduction system of IP receptors, 
there have been several reports that PGI2 and its analogs cause increases 
in intracellular Ca2+ levels and evoke smooth muscle contraction (26, 27). 
In addition, IP receptor agonist-induced inositol phosphate breakdown and 
inositol trisphosphate formation have also been reported in mouse thymus 
medulla (15). In order to clarify which signaling pathway is involved in 
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IP-mediated hepatocyte mitogenesis, we pharmacologically investigated 
which signal transduction pathways are mediated by IP receptor 
stimulation. As shown in Fig. 4, IP receptor agonist-induced hepatocyte 
mitogenesis was inhibited by the PLC inhibitor, U-73122 (28), but not by 
its inactive analog U-73343. Therefore, a primary mechanism by which 
hepatocyte IP receptors in primary cultures mediate PGI2 or 
carbaprostacyclin-induced hepatocyte DNA synthesis and proliferation is 
likely to be via stimulation of phosphatidylinositol-phospholipase C and 
increased Ca2+ mobilization. If this is indeed true, then these responses 
may also be stimulated by the Ca2+-ionophore ionomycin, which increases 
Ca2+ influx into cultured hepatocytes. Conversely, the Ca2+ channel blocker 
verapamil should inhibit DNA synthesis and proliferation induced by IP 
receptor agonists. Indeed both ionomycin and verapamil had these effects 
in our experiments as shown in Fig. 4. Therefore, activation of the 
PLC/Ca2+ pathway by IP receptor agonists appears to be essential for 
triggering hepatocyte DNA synthesis and proliferation. 
On the other hand, it appears unlikely that (Gq)/PLC/protein kinase C, or 
adenylate cyclase/protein kinase A, contribute to IP receptor-agonist 
induced hepatocyte mitogenesis. Thus neither an inhibitor of protein 
kinase C, sphingosine (29), the direct inhibitor of adenylate cyclase, 
2,4-dideoxyadenosine (30), nor the inhibitor of protein kinase A, H-89 (31), 
affected DNA synthesis or proliferation (Fig. 4). 
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Specific inhibitors of growth-related signal transducers, an EGF-receptor 
tyrosine kinase inhibitor AG1478 (32), a phosphatidylinositol-3-kinase 
(PI3K) inhibitor LY294002 (33), a MAP kinase kinase inhibitor PD98059 
(34), and a P70 S6 kinase inhibitor rapamycin (35) attenuated IP receptor 
agonist-stimulated hepatocyte DNA synthesis and proliferation (Fig. 5). 
Therefore, mitogenic signaling through the IP receptor pathway also 
requires activation of a receptor tyrosine kinase, PI3K, MAP kinase kinase, 
and p70S6K (Fig. 5). Although both the IP receptor/(Gq)/PLC/Ca2+ 
signaling pathway and the tyrosine kinase/MAP kinase signaling pathway 
are critically involved in IP receptor agonist-induced hepatocyte DNA 
synthesis and proliferation, the links between these signaling pathways 
have not been characterized in detail. Moreover, there is currently little 
evidence that IP receptor/(Gq)/PLC/Ca2+ pathways directly stimulate (or 
phosphorylate) elements of the tyrosine kinase/MAP kinase signaling 
pathway to induce cell proliferation (36-38). 
In a previous study, we demonstrated that prostaglandin E2 induced 
hepatocyte DNA synthesis and proliferation through autocrine secretion of 
TGF-α, which, in turn, stimulated hepatocyte mitogenesis (24). Therefore, 
we hypothesized that the IP receptor/(Gq)/PLC/Ca2+ pathway might 
significantly stimulate secretion of a specific mitogen by cultured 
hepatocytes in an autocrine manner thereby inducing hepatocyte DNA 
synthesis and proliferation through stimulation of a downstream receptor 
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tyrosine kinase/MAP kinase pathway. Mitogens that could fulfill this 
requirement are TGF-α and IGF-I. Both TGF-α and IGF-I are reported to 
be primary mitogens that are synthesized and stored in parenchymal 
hepatocytes, and are highly active growth factors that stimulate hepatocyte 
DNA synthesis and proliferation (5, 39-42). Therefore, we examined the 
effects of monoclonal antibodies against the putative growth factors TGF-α 
and IGF-I, on IP receptor agonist-induced hepatocyte DNA synthesis and 
proliferation. As shown in Fig. 6, both PGI2- and carbaprostacyclin-induced 
hepatocyte DNA synthesis and proliferation were almost completely 
inhibited by the monoclonal antibody against TGF-α, but not by that 
against IGF-I. In addition, monoclonal antibodies against EGF and HGF 
(12.5 - 100 ng/ml) did not significantly affect hepatocyte DNA synthesis and 
proliferation induced by IP receptor agonists (data not shown). Therefore, 
we suggest that the cytokine TGF-α is stored within the parenchymal 
hepatocytes and its secretion to the extracellular medium is triggered via 
IP receptor stimulation. Based on the above pharmacological analysis, we 
propose that the IP receptor is linked to a G-protein (possibly Gq) and 
stimulates the activity of PLC. This causes an increase in intracellular Ca2+ 
levels, which induces TGF-α secretion in an autocrine manner. The 
secreted TGF-α can induce hepatocyte DNA synthesis and proliferation via 
the TGF-α receptor tyrosine kinase/phosphatidylinositol 3 kinase/p42 MAP 
kinase/p70 S6K pathway. 
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In conclusion, we provide evidence that IP receptor agonists are powerful 
initiators of DNA synthesis and proliferation in primary cultures of adult 
rat hepatocytes. Conversely, a thromboxane A2 receptor agonist opposes 
hepatocyte mitogenesis induced by IP receptor agonists. Based on the 
antibody neutralizing experiments the IP receptor-dependent autocrine 
secretion of TGF-α is an essential step in the stimulation of DNA synthesis 
and proliferation, which is mediated by a receptor tyrosine kinase/MAP 
kinase pathway. IP receptor agonist-induced TGF secretion and the 
mechanisms by which it functions and is regulated are currently under 
investigation. 
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Figure Legends 
 
Fig. 1 Time course of the induced stimulation of hepatocyte DNA synthesis 
and proliferation by IP receptor agonists. Freshly isolated hepatocytes were 
cultured in Williams’ medium E containing 5% newborn bovine serum, 0.1 
nM dexamethasone, 0.10 μg/ml aprotinin, and antibiotics (100 U/ml 
penicillin and 100 μg/ml streptomycin) at a cell density of 3.3 × 104 cell/cm2. 
After a 3 h-attachment period (time = 0), the medium was rapidly replaced 
with serum- and dexamethasone-free Williams’ medium E with or without 
10-8 M PGI2 or 10-9 M carbaprostacyclin, and cultured for the indicated 
times. Hepatocyte DNA synthesis and proliferation were determined as 
described in Materials and Methods. The rate of hepatocyte DNA synthesis 
is expressed as dpm/mg protein/h (A). Hepatocyte proliferation is expressed 
as the percent increase in total number of nuclei compared to the control 
culture (B). The results are expressed as the means ± S.E.M. of three 
experiments. *P < 0.05, **p < 0.01 compared with the respective control. 
 
Fig. 2 Dose-response effects of IP receptor agonists on hepatocyte DNA 
synthesis and proliferation. Freshly isolated hepatocytes were plated at a 
density of 3.3 × 104 cells/cm2 and cultured as described in the legend to Fig. 
1. After the medium change, the hepatocytes were cultured with various 
concentrations of PGI2, carbaprostacyclin, or U46619 for a further 4 h. The 
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rate of hepatocyte DNA synthesis is expressed as dpm/mg protein/h (A). 
Hepatocyte proliferation is expressed as the percent increase in total 
number of nuclei compared with the control culture (B). The results are 
expressed as means ± S.E.M. of three independent experiments. **P < 0.01 
compared with the control (medium alone). 
 
Fig. 3 Effects of CAY10441, SC-51322 and U46619 on hepatocyte DNA 
synthesis and proliferation induced by IP receptor agonists. Hepatocytes 
were plated at a density of 3.3 × 104 cells/cm2 and cultured as described in 
the legend to Fig. 1. After the medium change, the hepatocytes were 
cultured with 10-8 M PGI2 or 10-9 M carbaprostacyclin in the presence or 
absence of CAY 10441 (10-10 to 10-7 M), SC-51322 (10-10 to 10-7 M) or 
U46619 (10-10 to 10-7 M) for 4 h. The rate of hepatocyte DNA synthesis is 
expressed as dpm/mg protein/h (A). Hepatocyte proliferation is expressed 
as the percent increase in total number of nuclei compared with the control 
culture (B). The results are expressed as means ± S.E.M. of three 
independent experiments. *P < 0.05, **p < 0.01 compared with the 
respective control. 
 
Fig. 4 Effects of inhibitors of the adenylate cyclase/protein kinase A 
pathway or the phospholipase C/protein kinase C pathway on hepatocyte 
DNA synthesis and proliferation induced by PGI2 or carbaprostacyclin. 
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Hepatocytes were plated at a density of 3.3 × 104 cells/cm2 and cultured as 
described in the legend to Fig. 1. Specific inhibitors or an agonist were 
added together with 10-8 M PGI2 or 10-9 M carbaprostacyclin immediately 
after the medium change and the hepatocytes were cultured for a further 4 
h. Concentrations were as follows: 2,4-dideoxyadenosine, 10-6 M; H-89, 10-7 
M; U-73122, 10-6 M; U-73343, 10-6 M; sphingosine, 10-6 M; verapamil, 10-6 
M; somatostatin 10-7 M; ionomycin, 10-7 M. The rate of hepatocyte DNA 
synthesis is expressed as dpm/mg protein/h (A). Hepatocyte proliferation is 
expressed as the percent increase in total number of nuclei compared with 
the control culture (B). The results are expressed as means ± S.E.M. of 
three independent experiments. *P < 0.05, **p < 0.01 compared with the 
respective control. 
 
Fig. 5 Effects of specific inhibitors of growth-related signal transducers on 
hepatocyte DNA synthesis and proliferation induced by PGI2 or 
carbaprostacyclin. Hepatocytes were plated at a density of 3.3 × 104 
cells/cm2 and cultured as described in the legend to Fig. 1. Specific 
signal-transducer inhibitors were added without or with 10-8 M PGI2 or 10-9 
M carbaprostacyclin immediately after the medium change, and the cells 
were cultured for a further 4 h. The concentrations were as follows: 
AG1478, 5 x 10-7 M; LY294002, 10-7 M; PD98059, 10-6 M; and rapamycin, 
10 ng/ml. The rate of hepatocyte DNA synthesis is expressed as dpm/mg 
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protein/h (A). Hepatocyte proliferation is expressed as the percent increase 
in total number of nuclei compared with the control culture (B). The results 
are expressed as means ± S.E.M. of three independent experiments. *P < 
0.05, **p < 0.01 compared with the respective control. 
 
Fig. 6 Effect of  specific inhibitors of growth-related signal transducers on 
receptor tyrosine kinase and MAP kinase activity induced by PGI2 or 
carbaprostacyclin. Freshly isolated hepatocytes were plated at a density of 
3.3 × 104 cells/cm2 and cultured as described in the legend to Fig. 1. After a 
medium change, hepatocytes were cultured with IP receptor agonists with 
or without specific inhibitors of signal transducers for 3 or 5 min. Receptor 
tyrosine kinase and MAP kinase activities were determined by Western 
blotting analysis as described in the Materials and Methods. 
Phosphorylated receptor tyrosine kinase (P-p175 kDa) and total receptor 
tyrosine kinase protein (p175 kDa) (A). Phosphorylated MAP kinase 
isoforms (P-p42 kDa, P-p44 kDa) and total MAP kinase protein (p42 kDa, 
p44 kDa) (B). Concentrations were as follows: PGI2, 10-8 M; 
carbaprostacyclin, 10-9 M; somatostatin, 10-6 M; AG1478, 10-7 M; LY294002, 
10-7 M; and PD98059, 10-6 M. The results are expressed as the means ± 
S.E.M. of three different experiments. *P<0.05, **p<0.01 compared with 
respective controls. 
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Fig. 7 Effects of monoclonal antibodies against TGF-α or IGF-I on IP 
receptor agonist-induced hepatocyte DNA synthesis and proliferation. 
Hepatocytes were plated at a density of 3.3 × 104 cells/cm2 and cultured as 
described in the legend to Fig. 1. After the medium change, hepatocytes 
were treated with 10-8 M PGI2 or 10-9 M carbaprostacyclin for 4 h in the 
presence or absence of TGF-α-neutralizing antibody or IGF-I-neutralizing 
antibody (2.5 - 100 ng/ml). The rate of hepatocyte DNA synthesis is 
expressed as dpm/mg protein/h (A). Hepatocyte proliferation is expressed 
as the percent increase in total number of nuclei compared with the control 
culture (B). The results are expressed as means ± S.E.M. of three 
independent experiments. *P < 0.05, **p < 0.01 compared with the 
respective control. 
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